- Home
- ASYS vs CUE Comparison
ASYS vs CUE Comparison
Compare ASYS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASYS
- CUE
- Stock Information
- Founded
- ASYS 1981
- CUE 2014
- Country
- ASYS United States
- CUE United States
- Employees
- ASYS N/A
- CUE N/A
- Industry
- ASYS Industrial Machinery/Components
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ASYS Technology
- CUE Health Care
- Exchange
- ASYS Nasdaq
- CUE Nasdaq
- Market Cap
- ASYS 59.4M
- CUE 48.0M
- IPO Year
- ASYS N/A
- CUE 2018
- Fundamental
- Price
- ASYS $4.81
- CUE $0.74
- Analyst Decision
- ASYS
- CUE Strong Buy
- Analyst Count
- ASYS 0
- CUE 3
- Target Price
- ASYS N/A
- CUE $3.00
- AVG Volume (30 Days)
- ASYS 40.9K
- CUE 323.3K
- Earning Date
- ASYS 08-06-2025
- CUE 08-13-2025
- Dividend Yield
- ASYS N/A
- CUE N/A
- EPS Growth
- ASYS N/A
- CUE N/A
- EPS
- ASYS N/A
- CUE N/A
- Revenue
- ASYS $90,826,000.00
- CUE $7,991,000.00
- Revenue This Year
- ASYS N/A
- CUE N/A
- Revenue Next Year
- ASYS $28.60
- CUE $23.84
- P/E Ratio
- ASYS N/A
- CUE N/A
- Revenue Growth
- ASYS N/A
- CUE 13.83
- 52 Week Low
- ASYS $3.20
- CUE $0.45
- 52 Week High
- ASYS $6.96
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ASYS 65.20
- CUE 51.10
- Support Level
- ASYS $4.66
- CUE $0.65
- Resistance Level
- ASYS $4.94
- CUE $0.83
- Average True Range (ATR)
- ASYS 0.25
- CUE 0.07
- MACD
- ASYS 0.04
- CUE 0.01
- Stochastic Oscillator
- ASYS 86.14
- CUE 30.43
About ASYS Amtech Systems Inc.
Amtech Systems Inc is a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon carbide (SiC) and silicon power chips, electronic assemblies, and light-emitting diodes (LEDs). the company has two segments; based on the industries served: Thermal Processing Solutions (formerly called Semiconductor) and Semiconductor Fabrication Solutions (formerly called Material and Substrate). Maximum revenue is generated from Thermal Processing Solutions. Maximum revenue is from Asia Region.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.